Gossamer Bio (GOSS) Other financing activities (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Other financing activities of $220000.0 for Q1 2026, up 66.67% year-over-year from $132000.0 in Q1 2025, and up 47.65% quarter-over-quarter from $149000.0 in Q4 2025.
Gossamer Bio (GOSS) Other financing activities (2019 - 2026) Analysis & Trends
Gossamer Bio's Other financing activities history runs 8 years deep, the most recent figure standing at $220000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 66.67% year-over-year to $220000.0; the TTM figure through Mar 2026 stood at $928000.0 (up 603.03% YoY), while the FY2025 annual figure was $840000.0, changed N/A from the prior year.
- Other financing activities for Q1 2026 stood at $220000.0, up from $149000.0 in the prior quarter.
- The five-year high for Other financing activities was $201.0 million in Q3 2023, with the low at -$200.9 million in Q4 2023.
- The 5-year median for Other financing activities is $184500.0 (2025), against an average of $107428.6.
- Peak annual rise in Other financing activities reached 18716.1% in 2023, while the deepest fall reached 16433.25% in 2023.
- Gossamer Bio's Other financing activities stood at -$1.2 million in 2022, then plunged by 16433.25% to -$200.9 million in 2023, then surged by 99.83% to -$348000.0 in 2024, then surged by 142.82% to $149000.0 in 2025, then surged by 47.65% to $220000.0 in 2026.
- Business Quant data shows GOSS's Other financing activities at $220000.0 in Q1 2026, $149000.0 in Q4 2025, and $465000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 220,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Dec 31, 2025 | 149,000.00 |
| Dec 31, 2025 | 149,000.00 |
| Sep 30, 2025 | 465,000.00 |
| Sep 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Sep 30, 2024 | -348,000.00 |
| Sep 30, 2024 | -348,000.00 |
| Jun 30, 2024 | 348,000.00 |
| Jun 30, 2024 | 348,000.00 |
| Dec 31, 2023 | -200.88 Mn |
| Dec 31, 2023 | -200.88 Mn |
| Sep 30, 2023 | 200.96 Mn |
| Sep 30, 2023 | 200.96 Mn |
| Mar 31, 2023 | 367,000.00 |
| Mar 31, 2023 | 367,000.00 |